News | January 20, 2026
Alto Neuroscience bags new US patent for depression drug ALTO-207
ALTO-207 combines pramipexole, a dopamine D3-preferring D3/D2 agonist approved for Parkinson’s disease
ALTO-207 combines pramipexole, a dopamine D3-preferring D3/D2 agonist approved for Parkinson’s disease
Improvements were also seen in complete response rates, duration of response, and time to next treatment
The researchers removed a chemical group commonly used in previous NK1R drugs and replaced it with a novel molecular scaffold
The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of June 10, 2026
The trial supports the potential for another chemotherapy backbone option that may be paired with encorafenib plus cetuximab in this patient population
Diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma (NHL) in adults, represents 40% of all cases worldwide
Abbott’s latest innovation promises to shift diabetes management from reactive to proactive
ICC is a highly aggressive liver cancer arising from the intrahepatic biliary epithelium
Despite some promising subgroup signals, the company indicated it will not pursue further psychiatric trials
Tolebrutinib had been provisionally approved in the United Arab Emirates in July 2025 for nrSPMS to slow disability accumulation independent of relapse activity
Subscribe To Our Newsletter & Stay Updated
